|
India’s nutraceutical market targets global manufacturing hub status, with compliance infrastructure in focus
|
|
Nandita Vijayasimha, Bengaluru
September 05 , 2026
|
|
|
India is positioning itself as a potential global production and export nutraceutical hub, aided by its pharmaceutical expertise, diverse botanical resources and expanding production ecosystem. The next phase of growth depends on strengthening compliance infrastructure supported by recent government initiatives mandating transparent product classification, robust quality-control systems, globally aligned standards, traceability and streamlined export procedures.
Dr. Saurabh Arora, managing director, Auriga Research noted that across the industry, we are already seeing the old approach of assembling key ingredients giving way to something closer to pharmaceutical rigour, standardised, clinically supported inputs at effective doses, backed by traceable sourcing and robust quality systems. That shift is not incidental. Inconsistent quality has at times, cost Indian suppliers, diverting demand to sourcing hubs which buyers trust more. Manufacturing capacity without compliance infrastructure simply results in trust issues.
What earns a reliable hub status is the infrastructure beneath the volume where validated analytical methods for both safety, including heavy metals, pesticides and microbiological limits, and functional quality through bioactive quantification, particularly for complex botanical mixtures are deployed, he added.
We have seen this play out before in pharmaceuticals. India's global credibility there was not built on capacity alone, but on regulatory and quality systems that let buyers stop verifying every batch themselves. Nutraceuticals need that same foundation first, Dr Arora told Pharmabiz.
Now India’s wellness economy is scaling faster than its scientific validation ecosystem. This is the defining tension in the industry today as consumer demand has moved past basic safety toward evidence-backed claims. But the validation infrastructure needed to support these claims has not kept pace. New brands and product launches multiply every quarter, while the systems that ought to back these like testing laboratories, standardisation protocols and clinical research capacity, are expanding far more slowly, Dr Arora pointed out.
This is because validation infrastructure takes longer to build than a product lines. Analysing complex, multi component botanical mixtures requires sophisticated, well-validated methods that laboratories spend years developing. Clinical studies demand proper protocols, adequate sample sizes, Good Clinical Practice and peer reviewed publication, are not compressed to match a brand's launch calendar. The result is a widening gap highlighting that a wellness economy confident in its growth story, resting on a scientific foundation that has not grown at the same rate. To close this gap, the industry priority for the next few years should not be to open new SKUs (stock keeping units), said Dr Arora.
Definitely, scientific credibility will define the next phase of India’s nutraceutical growth. The market is maturing past the point where compliance alone sets a brand apart. Buyers increasingly expect clear, evidence-backed claims, not merely products that clear a regulatory bar. That expectation rests on validated raw material sourcing, rigorous analytical testing, and clinical evidence robust enough to survive peer review. A formulation is only as credible as the sourcing behind it, and a clinical claim is only defensible if the tested batch matches what is sold at scale, said Dr Arora.
For international markets especially, peer reviewed publication and studies aligned with global clinical norms matter because they speak the evidentiary language buyers already trust. This is the same standard pharmaceutical companies meet to earn credibility abroad. As the market matures, companies that build this full pipeline will have an advantage because their claims can hold up under scrutiny, not just at launch. That is what will ultimately separate sustainable growth from short term market expansion, said Dr Arora.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|